Bio-Techne Corp

371.96+10.84+3.00%Vol 60.19K1Y Perf -22.12%
Aug 10th, 2022 13:04 DELAYED
BID371.96 ASK372.71
Open369.49 Previous Close361.12
Pre-Market- After-Market-
 - -%  - -
Target Price
507.14 
Analyst Rating
Moderate Buy 1.67
Potential %
36.34 
Finscreener Ranking
★★★     48.79
Insiders Trans % 3/6/12 mo.
-50/-50/-97 
Value Ranking
★+     43.70
Insiders Value % 3/6/12 mo.
-92/-92/-100 
Growth Ranking
★★★★★     73.16
Insiders Shares Cnt. % 3/6/12 mo.
-91/-91/-100 
Income Ranking
★+     36.95
Price Range Ratio 52W %
23.87 
Earnings Rating
Buy
Market Cap14.59B 
Earnings Date
4th Aug 2022
Alpha0.01 Standard Deviation0.09
Beta1.22 

Today's Price Range

362.91374.64

52W Range

318.07543.85

5 Year PE Ratio Range

34.20114.40

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-7.84%
1 Month
-2.38%
3 Months
2.73%
6 Months
-14.60%
1 Year
-22.12%
3 Years
88.00%
5 Years
209.31%
10 Years
450.44%

TickerPriceChg.Chg.%
TECH371.9610.84003.00
AAPL168.063.14001.90
GOOG120.793.29002.80
MSFT288.356.05002.14
XOM91.500.91001.00
WFC44.601.19742.76
JNJ169.93-0.2480-0.15
FB196.640.99000.51
GE77.402.47003.30
JPM118.493.11002.70
 
ProfitabilityValueIndustryS&P 500US Markets
68.00
22.40
31.70
21.70
24.61
RevenueValueIndustryS&P 500US Markets
817.37M
20.83
13.70
12.70
DividendsValueIndustryS&P 500US Markets
0.38
1.28
0.00
0.00
Payout ratio27.00
Earnings HistoryEstimateReportedSurprise %
Q04 20221.861.881.08
Q03 20221.751.9612.00
Q02 20221.591.600.63
Q01 20221.541.561.30
Q04 20211.471.6713.61
Q03 20211.241.6129.84
Q02 20211.221.263.28
Q01 20211.011.1513.86
Earnings Per EndEstimateRevision %Trend
6/2022 QR1.860.54Positive
6/2022 FY7.083.96Positive
9/2022 QR2.016.91Positive
6/2023 FY8.352.08Positive
Next Report Date-
Estimated EPS Next Report1.86
Estimates Count3
EPS Growth Next 5 Years %26.00
Volume Overview
Volume60.19K
Shares Outstanding39.23K
Shares Float34.41M
Trades Count3.39K
Dollar Volume22.36M
Avg. Volume234.40K
Avg. Weekly Volume271.74K
Avg. Monthly Volume206.31K
Avg. Quarterly Volume225.14K

Bio-Techne Corp (NASDAQ: TECH) stock closed at 361.12 per share at the end of the most recent trading day (a -3.74% change compared to the prior day closing price) with a volume of 301.86K shares and market capitalization of 14.59B. Is a component of S&P 500, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 2600 people. Bio-Techne Corp CEO is Charles R. Kummeth.

The one-year performance of Bio-Techne Corp stock is -22.12%, while year-to-date (YTD) performance is -30.2%. TECH stock has a five-year performance of 209.31%. Its 52-week range is between 318.07 and 543.85, which gives TECH stock a 52-week price range ratio of 23.87%

Bio-Techne Corp currently has a PE ratio of 63.00, a price-to-book (PB) ratio of 7.88, a price-to-sale (PS) ratio of 16.14, a price to cashflow ratio of 41.00, a PEG ratio of 2.32, a ROA of 10.56%, a ROC of 12.19% and a ROE of 14.23%. The company’s profit margin is 24.61%, its EBITDA margin is 31.70%, and its revenue ttm is $817.37 Million , which makes it $20.83 revenue per share.

Of the last four earnings reports from Bio-Techne Corp, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.86 for the next earnings report. Bio-Techne Corp’s next earnings report date is -.

The consensus rating of Wall Street analysts for Bio-Techne Corp is Moderate Buy (1.67), with a target price of $507.14, which is +36.34% compared to the current price. The earnings rating for Bio-Techne Corp stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bio-Techne Corp has a dividend yield of 0.38% with a dividend per share of $1.28 and a payout ratio of 27.00%.

Bio-Techne Corp has a Sell technical analysis rating based on Technical Indicators (ADX : 12.81, ATR14 : 14.09, CCI20 : -11.18, Chaikin Money Flow : 0.27, MACD : 6.31, Money Flow Index : 56.29, ROC : -0.59, RSI : 39.00, STOCH (14,3) : 9.56, STOCH RSI : 0.00, UO : 52.71, Williams %R : -90.44), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bio-Techne Corp in the last 12-months were: Brenda S. Furlow (Option Excercise at a value of $1 961 499), Brenda S. Furlow (Sold 15 409 shares of value $7 708 924 ), Charles R. Kummeth (Option Excercise at a value of $19 170 783), Charles R. Kummeth (Sold 5 104 shares of value $1 862 960 ), David Eansor (Option Excercise at a value of $3 496 148), David Eansor (Sold 28 697 shares of value $14 461 920 ), James T. Hippel (Option Excercise at a value of $2 276 884), James T. Hippel (Sold 19 784 shares of value $10 222 375 ), John L. Higgins (Option Excercise at a value of $107 040), John L. Higgins (Sold 1 600 shares of value $583 964 ), Kim Kelderman (Option Excercise at a value of $375 291), Kim Kelderman (Sold 1 322 shares of value $687 560 ), N. David Eansor (Option Excercise at a value of $3 496 148), N. David Eansor (Sold 28 697 shares of value $14 461 920 ), Randolph C. Steer (Option Excercise at a value of $349 560), Randolph C. Steer (Sold 8 000 shares of value $4 079 822 ), Robert V. Baumgartner (Buy at a value of $105 765), Robert V. Baumgartner (Option Excercise at a value of $349 560), Robert V. Baumgartner (Sold 4 000 shares of value $1 942 183 ), Roeland Nusse (Option Excercise at a value of $562 800), Roeland Nusse (Sold 8 000 shares of value $3 852 128 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (83.33 %)
5 (83.33 %)
6 (85.71 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (16.67 %)
1 (16.67 %)
1 (14.29 %)
Summary RatingModerate Buy
1.67
Moderate Buy
1.67
Strong Buy
1.57

Bio-Techne Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

CEO: Charles R. Kummeth

Telephone: +1 612 379-8854

Address: 614 McKinley Place N.E., Minneapolis 55413, MN, US

Number of employees: 2 600

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

75%25%

Bearish Bullish

61%39%

Bearish Bullish

62%38%

Bearish Bullish

61%39%


News

Stocktwits